publication date: Dec 3, 2013
By Matthew Bin Han Ong
A new kind of clinical trial that will assign patients to therapy based on molecular characteristics of their disease is being launched by a coalition of government agencies, pharmaceutical companies, and a non-government organization.
The effort, called the lung cancer “Master Protocol,” is a phase II and phase III trial that would test five drugs, assigning patients to therapy based on tumor biomarkers.
The master protocol in advanced squamous cell lung cancer (S1400) is one of at least three next-generation trials now in the works at NCI and its clinical trials cooperative groups.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.